2024 Global Therapeutic Drug Monitoring (TDM) Market: Unmet Needs, Supplier Shares and Strategies, Segment Volume and Sales Forecasts for 28 Assays, Emerging Technologies and Trends, Instrumentation Pipeline, Growth Opportunities for Suppliers

This new 313-page report contains 83 tables and provides analysis of the global therapeutic drug monitoring testing market, including emerging tests, technologies, instrumentation, sales forecasts by country, market shares, and strategic profiles of leading suppliers. The report is available by section, and can be customized to specific information needs and budget. The report provides test volume and sales forecasts by country and market segment for the following assays:

• Amikacin
• Carbamazepine
• Cyclosporin
• Digoxin
• Everolimus
• Gentamicin
• Levetiracetam
• Lithium
• Methotrexate
• NAPA/Procainamide
• Phenobarbital
• Phenytoin
• Quinidine
• Sirolimus
• Tacrolimus
• Theophylline
• Tobramycin
• Topirimate
• Valproic Acid

VancomycinDuring the next decade, the TDM market will undergo significant transformation. These changes will be caused by convergence of new and more stringent regulations; advances in diagnostic technologies, system engineering, automation, and IT; and intensifying competition. Some segments will start resembling commodity markets, where product positioning and cost per test are more critical than underlying technology. This evolving marketplace will create exciting opportunities for a variety of new instruments, reagent systems, and auxiliary products, such as specimen preparation devices, controls, calibrators and others.

This unique worldwide market and technology assessment is designed to help current suppliers and potential market entrants identify and evaluate emerging opportunities and developed effective strategic responses. The study provides five-year forecasts for major TDM assays; compares features of leading analyzers; and profiles key competitors. Contains 313 pages and 83 tables